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M A T E R I A L S A N D M E T H O D S
Cord blood was collected from the placentas of 68 Whk (D)-negative, Du-negative, full term, appropriate for gestational 1 age infants born at the George Washington University Hospital and the William Beaumont Army Medical Center between January 1973 and March 1974. All study infants' mothers were Rho ( D ) positive. ABO and Rh typing and Coombs tests of mother and infant blood were done independently by two experienced blood he detection of anti-D in Rho (Dknegative infants born of Rho bank technicians using standard typing sera. The infants' cord (D)-positive mothers confirms the neonate's ability to respond to were collected and frozen at -200, ~h~ study infants were antigen exposure. If Rho ( D ) exposure produces sensitization only at seen once again between 1 and 9 months of age when a 3 . 0 -~l ~arturition as this study implies, then there may be an immuno~ro-blood sample was obtained by venipuncture. Before venipuncture, phylactic role for Rho immune globulin in the the parents were informed completely of the research nature of this ~r o i k c t and subsequently of itiresults. Five of 68 parents refused . -permission for venipuniture and those infants are not included in Rho (D) erythroblastosis fetalis continues to be a neonatal thedata. The venipuncture sera were frozen at -20,. problem the introduction of h u m a n i m m u n e globulin ~f~~~ collection, the sera samples were coded and assayed for in 1968 (2). Before that time, it was estimated that there were anti-D antibody by the standard Coombs test and by the auto-300,000 women of chiid-bearing age in the United States who had mated method described by Lalezari (8) , Since the automated been sensitized by a prior Rho (D)-positive fetus (I). With the advent of human Rho immune globulin, this number was expected method is said to be able to detect both complete (IgM) and ' incomplete (IgG) antibody at concentrations as low as I ng/ml, it to decrease to almost zero. Yet there persist two groups of women will reveal antibody that the Coombs test would miss, (8) . who continue to bear Rho erythroblastotic infants. The first are Precautions and controls as described by Lalezari (8) to eliminate Rho immune globulin failures estimated at approximately I90 of false positives were. taken. In addition, anti-D-positive samples women who are candidates for prophylaxis, most of whom were confirmed by using a 10-red cell panel of known antigenicity. probably have had a larger than usual fetal-maternal hemorrhage The results of positive anti-D levels at the various follow-up ages of the infants are presented in Table 1 . It is interesting to note that the highest incidence of recovery occurred between I and 3 months of age, indicating that the antibody may decrease as the infant becomes older.
DISCUSSION
The results of the present study indicate that some Rho (D)-negative infants who have no evidence of Rho (D) isoimmunization at birth do develop anti-D antibody in the first months of life. There are currently two hypotheses to explain this observation.
The first is that the infant is exposed to his mother's Rho (D)-positive erythrocytes during fetal life. Taylor (17) and Owen et al. (12) have suggested that fetal exposure may result in tolerance rather than sensitization. The data of Pollack et al. (13, 14) showing that 20--30% of susceptible Rho (D)-negative adults will not form anti-D after antigenic exposure support the concept of tolerance. There is, however, no direct evidence to support or refute this hypothesis, and clearly such a phenomena requires further study. Furthermore, if sensitization tather than tolerance occurred, one should detect anti-D in the infant's cord blood.
The alternative hypothesis IS that the lntant IS exposed to Rho (D) antigen during parturition. Levine and Waller ( l o ) have shown clearly that Rho (D)-positive erythrocytes given to the female neonate can result in an Rh, erythroblastotic infant from that exposed female's first pregnancy. In addition, if the neonate's sensitizing exposure occurred during parturition, one should not detect anti-D in cord blood but later in the infant's life.
With the technique of automated antibody detection, we have been unable to demonstrate antibody in cord blood of the Rho (D)-negative infants of whom at least 7 of 63 (1 I %) had detectable anti-D between 1 and 9 months of age. I t is noted in our data that the 17.1 % incidence of infant sensitization detected during the 1 -3-month test period correlated with the incidence of maternalfetal transfusion reported by Zarou et al. (20) . Such a correlation, coupled with the negative cord blood anti-D levels, supports infant sensitization at birth rather than during gestation. This supposition is supported by Beer and Billingham's (3) data which revealed that only 1 of 40 similar infants studied between 3 and 20 months of age demonstrated anti-D antibody. Presumably the antibody response may only be of sufficient titer for detection for a short period of tlme.
In support of maternal-fetal sensitization at birth, Zarou et al. (7), however, present documented paired data on both cord blood and follow-up blood antibody levels to support either hypothesis.
T o additionally refute placental transfusion during gestation as the sensitizing event, Freda (6) showed that minute fetal-maternal erythrocyte exchange during gestation is more important in the amnestic response of the already sensitized Rho (D)-negative mother than in the initiation of anti-D formation in the nonsensitized individual. Furthermore, the occurrence of an amnestic response during the first pregnancy of an Rho-negative mother who previously was exposed to Rho-positive erythrocytes is well documented (4, 10, 16, 18, 19) . These cited studies all include females who had their first Rho (D)-positive erythrocyte exposure many years (some as infants) before their first pregnancy and subsequently bore Rho (D) erythroblastotic infants, confirming that an earlier primary immunization is necessary for the amnestic response that occurred during these females' first Rho (D)-positive fetus pregnancy.
ABO incompatibility is a factor that further complicates the understanding of Rho (D) sensitization since the relationship of ABO incompatibility to Rho (D) sensitization and the amnestic response of pregnancy is incompletely understood. Although ABO incompatibility tends to protect the Rh, (D)-negative mother from sensitization by her Rho (D)-positive fetus (9) . there is no alteration of the severity of Rho erythroblastosis once sensitization has occurred (9) . It is interesting that none of the 15 infants in this study who had maternal-fetal ABO incompatibility and the 6 who had fetomaternal ABO incompatibility developed anti-D. This observation is especially interesting since the O infant at birth rarely has his own A or B antibody. Perhaps a placental factor is involved in the maternal-fetal ABO incompatibility. Further evaluation of this finding is necessary to understand whether ABO incompatibility is related to Rh sensitization of the susceptible infant.
S U M M A R Y
These data show that infants can respond to Rho (D)-positive erythrocytes with anti-D antibody formation. Furthermore, the data suggest that the infant's primary exposure to Rho-positive erythrocytes occurs during parturition rather than during gestation. This assumption is based on the inability to detect antibody from cord blood by the most sensitive technique currently available for measuring circulating antibody in infants who a few months later have easily detectable anti-D.
Although these data are preliminary, it is tempting to speculate that Rho human immune globulin would have a place in the immunoprophylaxis of Rho (D)-negative infants whose mothers are Rho (D) positive. Whether or not the efficacy of Rh, immune globulin would be the same in the neonate as in the adult is currently under investigation. If the data confirm our hypothesis, then another cause of primary Rho (D) immunization can be eliminated. No. positive In 1974, we described two sisters with normal serum folate concentration who excreted formiminoglutamic acid (FIGlu) in excessive amounts (l5), both about 600 mmol FIGlu/mol creatinine. We believe that they represent the first cases where a practically complete deficiency of formimino-L-glutamate:tetrahydrofolate-5-formiminotransferase can be postulated. Our cases did not respond to pharmacologic doses of folic acid. Recently Perry et al. (17) described two other cases with apparently the same metabolic error. They excreted markedly lower amounts of FlGlu under pharmacologic doses of folic acid. From the known catabolic pathway of histidine we also suspected an increase in the excretion of H P A (15). For the precise measurement of this compound in urine we developed a relatively simple mass fragmentographic method (16) . I n this report, the results of these measurements are presented.
MATERIALS AND METHODS
H P A was synthesized from L-glutamic acid according to the method of Dakin (10) . Similarly, trideutero-HPA was synthesized from 2,4,4-[ZH,J-DL-glutamic acid (19) . H P A was analyzed quantitatively as the N,O-permethyl derivative with trideutero-
